8,951,105 Shares in X4 Pharmaceuticals, Inc. $XFOR Bought by Empery Asset Management LP

Empery Asset Management LP purchased a new position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,951,105 shares of the company’s stock, valued at approximately $35,804,000. X4 Pharmaceuticals comprises 31.7% of Empery Asset Management LP’s investment portfolio, making the stock its largest position. Empery Asset Management LP owned approximately 0.10% of X4 Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of XFOR. Indivisible Partners bought a new stake in X4 Pharmaceuticals in the fourth quarter worth $40,000. Rhumbline Advisers increased its position in X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the last quarter. Two Sigma Investments LP bought a new stake in X4 Pharmaceuticals in the third quarter worth $47,000. Bank of America Corp DE increased its position in X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in X4 Pharmaceuticals during the fourth quarter valued at $104,000. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Trading Down 3.1%

NASDAQ XFOR opened at $3.73 on Thursday. The company’s 50-day moving average price is $4.10 and its 200-day moving average price is $3.88. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The stock has a market cap of $351.81 million, a PE ratio of -0.82 and a beta of 0.34. X4 Pharmaceuticals, Inc. has a 12 month low of $1.35 and a 12 month high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The firm had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $3.20 million. Equities research analysts forecast that X4 Pharmaceuticals, Inc. will post -0.77 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price objective on the stock. Leerink Partners assumed coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.38.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.